|
|
ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE
|
2R44CA114126-02
|
$419,983
|
$419,983
|
Lim, Mark
|
AMBERGEN, INC
|
|
|
Generation of a Modified DT_IL3 Fusion Toxin
|
1R43CA134162-01
|
$122,830
|
$122,830
|
VANDERSPEK, JOHANNA
|
ANJIN GROUP, INC.
|
|
|
Molecular Target Focused Discovery of Anticancer Drugs
|
2R01CA090441-06A2
|
$381,250
|
$53,375
|
PETTIT, GEORGE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-19
|
$481,201
|
$28,872
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
|
SV40 Pathogenesis of Human Infections
|
5R01CA104818-05
|
$467,229
|
$140,169
|
BUTEL, JANET
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
NR4A Nuclear Receptor Function in Leukemia
|
5R01CA111411-03
|
$258,529
|
$258,529
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
SPORE in Lymphoma
|
5P50CA126752-02
|
$2,266,618
|
$453,324
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Proteosome Inhibition Therapy for Hematologic Malignancy
|
5K23CA113775-03
|
$134,015
|
$67,008
|
HORTON, TERZAH
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mechanisms of Cellular Transformation by HTLV-1 TAX
|
5R01CA077371-10
|
$268,279
|
$268,279
|
Marriott, Susan
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-02S1
|
$117,286
|
$4,691
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-02
|
$1,515,000
|
$60,600
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mitotic Regulation of Apoptosis in Leukemia
|
5R01CA109478-03
|
$206,823
|
$206,823
|
PATI, DEBANANDA
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mechanism and Consequences of Telomere Dysfunction
|
1R01CA133249-01
|
$318,513
|
$159,257
|
Songyang, Zhou
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Regulation of p21waf1/cip1 by Rho and Ras signaling
|
5R01CA030721-06
|
$182,278
|
$18,228
|
OLSON, MICHAEL
|
BEATSON INSTITUTE FOR CANCER RESEARCH
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-25
|
$453,250
|
$4,533
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Training Patients and Partners for HSCT: A Novel Coping Skills Intervention
|
5R03CA130725-02
|
$84,500
|
$42,250
|
Lawsin, Catalina
|
BERNARD M. BARUCH COLLEGE
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-10
|
$128,678
|
$9,007
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Reconstitution of T cell immunity after UCB transplantation: The role of Treg
|
1R21CA123855-01A2
|
$391,915
|
$195,958
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Expression and Function of Tob in T Lymphocytes
|
7R01CA104596-04
|
$318,352
|
$127,341
|
BOUSSIOTIS, VASSILIKI
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Novel Strategies for Treatment of Myeloproliferative Disorders
|
1R01CA131664-01A1
|
$352,750
|
$352,750
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Oncogene-Induced Evasion from Apoptosis
|
5R01CA105306-04
|
$318,352
|
$318,352
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of Gab2 and Shp2 in Hematopoietic Signalling
|
5R01CA114945-11
|
$396,987
|
$396,987
|
NEEL, BENJAMIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Fusion Proteins in the Molecular Pathogenesis of APL
|
5R01CA074031-13
|
$351,467
|
$351,467
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Role of POZ-zinc finger proteins in hemopoietic malignacies
|
7R01CA102142-05
|
$330,443
|
$165,222
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
X-RAR alpha proteins: Molecualr Pathogenesis of Acute Promyelocytic Leukemia
|
7R37CA071692-12
|
$348,711
|
$348,711
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Mouse model of infant acute megakaryocytic leukemia
|
5K08CA111399-04
|
$134,379
|
$134,379
|
Raffel, Glen
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Suppression of FOXO3a as a determinant in Bcr-Abl-mediated transformation
|
1F32CA132365-01
|
$46,826
|
$46,826
|
Singh, Amrik
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting Leukemic Stem Cells
|
1R01CA138211-01
|
$350,261
|
$350,261
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
MOLECULAR BIOLOGY OF MYELOID DIFFERENTIATION
|
5R01CA041456-23
|
$443,800
|
$443,800
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Distinct acute myeloid leukemia subclasses with CEBPA mutations
|
5R01CA118316-02
|
$389,858
|
$389,858
|
TENEN, DANIEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Cyclic AMP-mediated apoptosis in lymphoid malignancies
|
5R01CA106705-04
|
$241,199
|
$241,199
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
|
|
Role of P80 pro-IL-16 in T Cell Malignancy
|
5R01CA100925-04
|
$282,526
|
$141,263
|
ZHANG, YUJUN
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
Oncogenic NOTCH Signaling
|
5P01CA119070-03
|
$986,393
|
$986,393
|
ASTER, JON
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alternative Entry Mechanism for Pathogenic Retroviruses
|
5R01CA104266-05
|
$259,594
|
$259,594
|
CUNNINGHAM, JAMES
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Aspartame Intake and the Risk of Cancer
|
5R03CA130054-02
|
$116,957
|
$38,596
|
SCHERNHAMMER, EVA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Notch Signaling in Lymphoid Neoplasia
|
5K22CA112538-03
|
$160,920
|
$160,920
|
Weng, Andrew
|
BRITISH COLUMBIA CANCER AGENCY
|
|
|
SIGNAL TRANSDUCTION AND CELL DEATH REGULATION
|
5P01CA069381-13
|
$1,715,290
|
$343,058
|
REED, JOHN
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
|
CANCER CENTER SUPPORT GRANT
|
5P30CA030199-28
|
$3,649,220
|
$72,984
|
VUORI, KRISTIINA
|
BURNHAM INSTITUTE FOR MEDICAL RESEARCH
|
|
|
Carle Cancer Center Community Clinical Oncology Program
|
2U10CA035195-25
|
$855,703
|
$8,557
|
ROWLAND, KENDRITH
|
CARLE CLINIC ASSOCIATION, P C
|
|
|
Eastern Cooperative Oncology Group Studies
|
5U10CA014548-34
|
$417,899
|
$29,253
|
AVERBOOK, BRUCE
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Non-natural Nucleoside Inhibitors of DNA Polymerases
|
5R01CA118408-04
|
$229,214
|
$114,607
|
BERDIS, ANTHONY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Role of Lipocalin 24p3 in Apoptosis and Leukemia
|
5K01CA113838-04
|
$151,294
|
$151,294
|
DEVIREDDY, LAXMINARAYANA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Mechanism of Steroid Action in Lymphoid Malignancy
|
5R01CA042755-22
|
$311,299
|
$155,650
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
|
2U01CA062502-15
|
$751,074
|
$45,064
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-18S3
|
$234,254
|
$4,685
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S1
|
$72,416
|
$1,448
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-19S2
|
|
$0
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-19
|
$5,104,000
|
$102,080
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
|
Cedar Rapids Oncology Project
|
2U10CA052352-19
|
$575,627
|
$5,756
|
WIESENFELD, MARTIN
|
CEDAR RAPIDS ONCOLOGY PROJECT
|
|
|
Variation in Ara-C Pathway Genes and Treatment Outcomes in AML
|
5R21CA119142-02
|
$152,926
|
$152,926
|
GOYAL, RAKESH
|
CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
|
|
Total relevant funding to Leukemia for this search: $216,373,807
|
